Serrano–Lowe oncogene-induced senescence experiment

Background

An active ras gene transforms immortal rodent cell lines to a tumorigenic state, while primary cells resist ras alone. Land, Parada, and Weinberg had shown in 1983 that primary embryo fibroblasts become tumorigenic only when ras arrives with a cooperating oncogene such as myc.² The same resistance appeared when ras was paired with viral proteins that disable the p53 or RB pathways. Those results left open what the primary cell does when ras arrives by itself, and Serrano’s group had recently identified p16 as an inhibitor of ras-driven proliferation.¹

Design

The experiment delivered oncogenic ras into primary human and rodent fibroblasts with retroviral vectors and followed the cells through the following days and weeks. The researchers measured DNA synthesis and growth arrest, recorded cell morphology, and assayed p53 and p16 protein levels. To test which pathways carried the response, they used rodent cells with inactivated p53 or p16 and human cells expressing the adenoviral protein E1A, which blocks the RB pathway. The comparison asked whether the arrest depended on the tumor suppressors that cooperating oncogenes normally disable.

Result

Oncogenic ras produced a permanent G1 arrest in primary cells. The arrested cells accumulated p53 and p16 and took on a morphology and gene-expression pattern that matched cells at the end of their replicative lifespan, so the authors classified the state as premature senescence. Inactivation of either p53 or p16 prevented the arrest in rodent cells, and E1A produced the same escape in human cells. The response therefore ran through the RB and p53 axes, the two pathways that cooperate to enforce cell-cycle exit, and ras drove the cell into that exit.¹

What it established

The experiment recast senescence as an active response to a specific oncogenic signal:

• Oncogenic ras can trigger senescence in primary cells within days, well before the cells reach the end of their replicative lifespan.
• The response requires intact p53 and p16–RB signaling, so it represents active tumor suppression.
• Transformation by ras requires the cell to disable that response, which supplies a mechanism for the cooperation seen between oncogenes.

This result supplied the experimental basis for oncogene-induced senescence as a distinct form of the senescence program, alongside replicative senescence and therapy-induced senescence. It also placed senescence among the tumor-suppressor mechanisms whose persistence shapes aging tissue, and it gave the Baker INK-ATTAC experiment a defined cell population, p16-positive senescent cells, to follow in live animals.

Limits and later work

The experiment used cultured primary fibroblasts and measured a phenotype over weeks in a dish, so it described a cellular response that later work connected to tumor development. The authors noted that escaping the arrest may matter during multistep tumorigenesis, which later mouse models tested by deleting ras-induced senescent cells in premalignant lesions. The p16 protein proved to mark several kinds of senescent cell, and p16 accumulation became the common biomarker that connected oncogene-induced senescence to other senescent and quiescent states.

See also

• Cellular senescence
• p16^INK4a (CDKN2A)
• p53
• KRAS
• History of biogerontology

References